Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Off-target messenger RNAs (mRNAs) with partial sequence complementarity represent a significant challenge in the development of RNA interference (RNAi) based therapeutics, such as short hairpin RNAs (shRNAs). These unintended targets are silenced when the guide strand of the RNAi molecule binds to an mRNA transcript that shares sequence similarity, particularly within the 'seed region' (nucleotides 2-8), even if the overall match is imperfect (Jackson et al., 2003; Birmingham et al., 2006). This phenomenon mimics the natural microRNA (miRNA) regulatory pathway, leading to the downregulation of genes that were not the intended focus of the therapy. Such off-target effects can result in significant cellular toxicity, altered phenotypes, and misleading experimental results in both research and clinical settings (Grimm et al., 2006). Managing these interactions requires sophisticated bioinformatic design, chemical modifications to the RNA strands, and careful dose titration to minimize adverse effects while maintaining therapeutic efficacy (Jackson & Linsley, 2010).
Unintended gene silencing occurs when the guide strand of an shRNA or siRNA binds to an mRNA with partial complementarity, typically involving the 'seed region' (nucleotides 2-8). This interaction mimics the endogenous microRNA (miRNA) pathway, leading to translational repression or mRNA degradation of non-target genes via the RNA-induced silencing complex (RISC).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Off-target messenger RNA (mRNA) with partial sequence complementarity (Off-target mRNA).